Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods are increasingly used for minimal residual disease detection (MRD), and provide useful prognostic information. In this review, current approaches for MRD detection in indolent lymphomas are summarized. In addition, the prognostic aspects of molecular monitoring after transplantation procedures are discussed. The experience accumulated over the past decade shows that PCR analysis has a prognostic impact in several therapeutic programs including conventional and high-dose regimens. Major advantages coming from the introduction of molecular monitoring in clinical programs have been: (1) a rapid evaluation of the anti-tumor activity of innovative treatments; and (2) an early identification of patients with a high-risk of disease recurrence.
Introduction
During the last 10 years, the treatment of non-Hodgkin's lymphoma (NHL) has dramatically changed. 1, 2 Major advances in the field have been the introduction of high-dose chemotherapy regimens followed by autologous or allogeneic transplantation of hematopoietic cells, [3] [4] [5] [6] [7] [8] the development of novel drugs such as purine analogues 9 and monoclonal antibodies, 10 and the use of innovative methods for ex vivo manipulation of autologous stem cells. [11] [12] [13] [14] [15] [16] [17] [18] [19] Treatment evolution has been particularly remarkable in low grade subtypes, where palliative approaches have been progressively substituted by treatments aimed at improving disease-free survival and possibly curing at least patients younger than 60-65 years.
Despite the introduction of these novel approaches, a sizeable fraction of patients achieving clinical complete remission actually relapse and die of their disease. The relapse is presumably caused by the persistence of small numbers of lymphoma cells that are below the limit of detection of standard diagnostic procedures. Therefore, considerable effort has been made over the past decade to develop new techniques that allow the detection of extremely small numbers of tumor cells. Among these techniques, the most sensitive and widely used is the polymerase chain reaction (PCR). Its use has been extensive in several hematological neoplasms, and the persistence of PCR detectable tumor cells has been correlated with increased likelihood of relapse in both myeloid and lymphoid neoplasms. In the NHL setting, several studies have been published on the prognostic significance of minimal residual disease (MRD) detection. Most of these studies focus on indolent lymphomas: small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), 17, 18 follicular (FCL) [19] [20] [21] and mantle cell lymphomas (MCL). 20, 22 This is mostly because these tumors, unlike more aggressive NHL histotypes, are disseminated disorders with frequent microscopic or submicroscopic bone marrow (BM) and peripheral blood (PB) involvement, and thus they represent ideal targets for MRD evaluation with PCR-based assays. 23, 24 In this review, we summarize the characteristics of the most frequently used strategies for PCR detection of residual disease in lymphoma patients. The clinical relevance of molecular monitoring after autologous or allogeneic transplantation will also be discussed.
PCR strategies for monitoring residual disease in indolent lymphomas
The essential requirement for a PCR assay is the presence of DNA sequences that are constantly detectable in the neoplastic population and constantly undetectable in normal hemopoietic cells. From these sequences primers and probes can be designed and used for MRD detection. There are two categories of tumor molecular markers: tumor-specific translocations, and antigen-receptor rearrangements. Tumor translocations have two major advantages: first, MRD detection is relatively simple since it involves only a PCR amplification possibly followed by probe hybridization; second, these chromosonal aberrations are pathogenetically related to the neoplastic process, they represent a stable molecular marker, and they are usually not detected in normal cells. The main disadvantage of translocation-based markers is that they provide a molecular marker only for a subset of patients. Such a fraction is highly variable depending on the lymphoma subtype: FCLs harbor the t(14;18) translocation in approximately 60-80% of cases, 19 whereas t(11;14) translocation is detectable in 70-100% of MCL patients. 22 Moreover, in several NHL subtypes no chromosomal translocation is presently available for MRD evaluation.
The rearrangement of immunoglobulin heavy-chain (IgH) and T cell receptor genes (TCR), has a wider applicability and can be used as molecular markers in the vast majority of lymphoid tumors. However, their use for PCR detection of MRD is somehow more complex than chromosomal translocations since it requires the sequencing analysis of rearranged variable region in order to design tumor-specific primers and probes. 25, 26 In addition, clonal evolution is a potential problem associated with the use of IgH or TCR rearrangements.
immature disorders such as acute lymphoblastic leukemia, and it does not take place in mature lymphoid tumors such as indolent lymphomas and myelomas.
So far, the three most widely used clonal markers in NHL patients are the t(14;18), the t(11;14) and the IgH gene rearrangement. The t(14;18) was the first lesion routinely employed for MRD analysis in NHL and it is detectable in approximately 60-80% of FCL patients and in 20% of diffuse large cell lymphomas. 28, 29 In this translocation, the Bcl-2 proto-oncogene on chromosome 18 is juxtaposed to the IgH locus on chromosome 14. Breakpoints are located at two main clusters 3Ј to the Bcl-2 coding region, named major breakpoint region (MBR) and minor cluster region (mcr). 30, 31 The t(14;18) translocation upregulates expression of the Bcl-2 gene product that induces prolonged cell survival by blocking programed cell death. The two breakpoint regions require different sets of primers for PCR amplification. MRD evaluation is performed by PCR amplification of the junctional region using a 5Ј primer derived from the Bcl-2 locus and a 3Ј primer derived from the JH region of IgH genes. PCR products can be hybridized to a Bcl-2 specific probe or, alternatively, reamplified using a second set of internal primers: the socalled nested-PCR. Both hybridization and nested-PCR are extremely sensitive and specific techniques and can routinely detect one lymphoma cell in 10 5 -10 6 normal cells.
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The t(11;14) fuses the Bcl-1 locus with the IgH locus and is detected by cytogenetic or Southern blot analysis in the vast majority of MCL patients (70-100%). This translocation activates the cyclin D1 (PRAD-1/CCND1) gene. Cyclin D1 is a G1 cyclin that participates in the control of cell cycle progression at the G1-to S-phase transition. Overexpression of this cyclin induces a shortened G1 phase and may function as an oncogene, cooperating with other oncogenic factors in cellular transformation. Breakpoints on chromosome 11 have been found dispersed over more than 100 kb of genomic DNA. Three clusters have been identified so far; the most important is named the major translocation cluster and contains approximately 30-50% of these translocations. This DNA region represents a suitable target for PCR amplification. Because of the large breakpoint areas, less than 30% of MCL patients will have a rearrangement that can be detected by PCR. 22, 32 PCR detection of the t(11;14) is usually performed employing semi-nested PCR: two consecutive amplifications are performed, using the same 3Ј primer derived from the JH region and two 5Ј primers derived from the major translocation cluster of the Bcl-1 locus. This approach can usually detect one lymphoma cell out of 10 5 normal cells. 22 The IgH gene rearrangement has been used in different subtypes of NHL, including SLL/CLL, FCL and MCL. 17, 18, 22, 25, 26, 33 This method relies on the amplification and sequencing of the IgH rearranged variable region (VDJ). VDJ amplification is performed using consensus primers derived from the leader or framework regions of IgH genes. 26 Amplified VDJs are then sequenced to identify the three complementarity-determining regions (CDRs). These regions code for the antigen-binding site and are unique to each B cell clone. From the CDR2 and CDR3, oligonucleotide primers and probes are usually designed. This method can provide a tumor marker in approximately 80% of lymphoma and myeloma patients. PCR analysis using the IgH rearrangement has specificity and sensitivity similar to translocation-based assays. 26 A potential limitation of PCR detection of residual disease is the qualitative and not quantitative nature of the analysis. Although qualitative analysis has been extremely useful in several clinical settings, the development of accurate and reproducible methods for quantitative analysis of MRD is required. This is of particular interest in evaluating the kinetic of the tumor clone in those diseases in which the persistence of PCR detectable tumor cells is frequently observed with standard qualitative methods. Traditional quantitative and semiquantitative PCR approaches of end-product DNA analysis, limiting dilution strategies and competitive PCR are labour intensive, show a limited dynamic range and often give nonreproducible results, and thus are of limited applicability in the clinical setting. 34 Recently, the introduction of the TaqMan technology and the development of analytical thermal cyclers have allowed the development of extremely powerful systems for quantitative analysis. These methods are highly accurate, mostly because they allow direct measurement of quantitative data at the beginning of the exponential phase of PCR amplification and thus eliminate biases taking place during late post-exponential phases of the reaction and during post-PCR manipulation of samples. Several different tumor translocations including the t(14;18) as well as the IgH rearrangement [35] [36] [37] have been used as targets for MRD detection using TaqMan-based approaches. However, large studies, investigating the prognostic relevance of quantitative evaluation of MRD in lymphoid tumours, are still awaited.
Molecular analysis as a tool to assess the efficacy of in vitro purging procedures
High-dose chemotherapy regimens followed by autologous transplantation with BM or peripheral blood progenitor cells (PBPC) are increasingly used for the treatment of indolent lymphomas.
3,4,6-8 However, since these neoplasms have a high degree of PB and BM involvement, stem cell grafts are often contaminated by occult tumor cells that can contribute to disease relapse. 38 In vitro purging of stem cell grafts has been regarded as a potentially useful method to obtain a significant reduction and possibly the eradication of contaminating tumor cells. PCR analysis has been extensively used in this setting: the efficacy of purging procedures in different diseases has been evaluated giving the percentage of patients in which grafts were successfully cleared from residual lymphoma cells. In addition, correlations, between infusion of PCR-negative grafts and disease-free survival, have been investigated. 19, 20, 24 Investigators from Dana Farber Cancer Institute, Boston, have pioneered large-scale in vitro purging techniques: anti-B cell monoclonal antibodies together with complementmediated lysis have been used to purge marrow grafts from patients with FCL, SLL/CLL and MCL. 18, 23, 24 Significant differences between lymphoma subtypes were observed: in FCL residual tumor cells became undetectable in approximately 50% of patients, and the reinfusion of a PCR-negative graft was correlated with a better disease-free survival. 24 A similar finding has been observed in a panel of 21 SLL/CLL patients: a correlation between the reinfusion of PCR-positive grafts and increased likelihood of relapse has been documented. 18 However, very recent data on a larger panel of SLL/CLL patients seem to provide less optimistic results with more than 75% of patients still harboring residual tumor cells after in vitro purging. 39 The same purging procedure has been applied to MCL patients, giving unsatisfactory results. Marrow grafts resulted virtually always PCR-positive after the in vitro treatment with monoclonal antibodies. 22 It should be pointed out, however, that the use of in vitro purging for FCL patients is still a matter of controversy. Pappa et al 21 have used in vitro purging for FCL patients, and they have shown a clearance of PCR-detectable lymphoma cells in less than 15% of cases. There is not a clear explanation for these conflicting findings. Both differences between purging procedures, and sensitivity/specificity of PCR assays have been postulated. Although most purging studies in NHL were performed using negative selection, other purging techniques have been recently developed. Positive selection of CD34 + cells has recently gained considerable interest. Some studies have shown that CD34 + selection was successful in eradicating residual lymphoma cells from both PBPC and BM grafts in FCL patients. 14, 40 In contrast, CD34 + selection was largely unsuccessful in SLL/CLL patients. 17 Thus, both negative and positive selection methods proved to be successful in eradicating PCR-detectable disease in a significant proportion of FCL patients. Comparative studies are probably required to define which approach should be considered more appropriate and cost-effective.
Role of molecular monitoring in the prediction of relapse following conventional and high-dose chemotherapy treatments
An important application of MRD assays is the molecular monitoring of patients achieving complete remission. The term 'complete remission' is used to define a category of patients in whom there is no evidence of disease using standard laboratory and clinical procedures. This condition encompasses different clinical situations including complete eradication of the tumor clone, long-term persistence of tumor cells with no tendency to relapse, and presence of residual tumor cells giving rise to overt relapse during the subsequent follow-up period. While conventional approaches are unable to distinguish between these situations, sequential analysis of MRD has provided novel insights on the behavior of the residual neoplastic population and allowed the identification of different prognostic subgroups. The studies with the longest observation period have been performed in FCL patients undergoing autologous transplantation with purged BM cells. 19 PCR analysis was performed serially on BM and PB samples obtained at different time-points after transplantation. Three major patterns of disease evolution have been observed: (1) some patients displayed persistent PCR positivity and subsequently relapsed; (2) others resulted PCR-negative immediately after autografting and then regained a PCR-positive status, and they are at high-risk for relapse; and (3) other patients had a persistent PCR-negative status or achieved molecular remission shortly after; these patients are characterized by a low relapse rate. 19 A similar correlation between molecular monitoring and disease-free survival has also been observed in patients undergoing high-dose chemotherapy followed by autografting of unmanipulated PBPC. We have shown that patients, harvesting PCR-negative BM and/or PBPC grafts, displayed a persistent PCR negativity after transplantation. Among these patients none have relapsed, while disease recurrences were frequently observed among patients with persistent PCR positivity. 20 Similar results in terms of correlation between PCR positivity and high incidence of relapse were also observed by Hardingham et al. 41 In addition, Moos et al 42 have shown that the PCR status before autografting and the PCR status assessed at follow-up examinations are significant prognostic parameters for relapse-free survival in patients with FCL.
A recent report from the MD Anderson Cancer Center, Houston reported a high rate of molecular remissions after conventional-dose chemotherapy (66%). They could demonstrate a correlation between molecular response during the first year of therapy and failure-free survival. 43 It is somehow difficult to compare these results with those obtained after purged or unpurged autografting. In the MD Anderson study, the achievement of molecular response was to a certain extent independent of the clinical response: one-third of patients in CR became PCR-negative, and one-third of patients in partial remission became PCR-negative as well. In contrast, the data from autografting studies derive from CR patients only. A recent report from Czuczman et al 44 has opened a novel field of investigation: they have shown that conventional chemotherapy in combination with anti-CD20 chimeric antibody is able to produce durable clinical and molecular remissions. The interesting point is that conventional chemotherapy with or without monoclonal antibodies may be able to produce molecular remissions. A careful long-term monitoring is required to ascertain the clinical relevance of molecular data in this setting. Randomized trials between conventional and high-dose chemotherapy are probably required.
Molecular monitoring has been also performed in MCL and SLL/CLL patients. These studies, however, have involved a smaller panel of patients. In SLL/CLL Provan et al showed a pattern similar to that observed in FCL, but with less satisfactory results. 18 Molecular follow-up data from SLL/CLL patients undergoing high-dose chemotherapy followed by autografting of unmanipulated PBPC were quite disappointing. Although clinical complete remissions were frequently achieved, the persistence of PCR positivity after transplantation represented a nearly constant finding. 45 In the MCL subtype, the vast majority of patients showed persistent PCR positivity after transplantation using both purged or unpurged autografting. 20, 22 These data are consistent with the clinical finding that these patients are not cured by autologous transplantation and actually relapse. Preliminary results, in a novel strategy combining high-dose chemotherapy and in vivo administration of chimeric anti-CD20 have been recently reported. PCR-negative PBPC grafts have been harvested, but the small number of patients and the short follow-up do not allow any definitive conclusions to be drawn as yet. 46 Allogeneic transplantation has recently gained considerable interest as salvage treatment for patients with relapsed or refractory indolent lymphomas. It has recently been published that a significant proportion of these patients experiences a prolonged disease-free survival. 47, 48 Unfortunately, few molecular data are available for this group of patients. Several long-term survivors experience prolonged clinical and molecular remissions even among MCL patients. 18, 22, 49 In the near future, we expect a wider application of allogeneic transplantation for the treatment of indolent lymphomas possibly associated with treatments aimed at modulating the graft-versus-tumor immune response. There is little doubt that PCRbased monitoring of MRD, using both qualitative and quantitative methods, will be extremely helpful to evaluate the effectiveness of such treatments and to tailor specific therapeutic modalities for patients at increased risk of relapse (ie programmed reinfusions of donor lymphocytes).
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Conclusion and future perspectives
The treatment of indolent lymphomas is a rapidly evolving field and novel treatments are constantly under evaluation. However, the prolonged natural history of these neoplasms is a potential obstacle to the rapid development of innovative therapeutic strategies since several years are usually required in order to draw definitive clinical conclusions on a given treatment. In recent years, considerable experience has been accumulated on PCR-based evaluation of MRD, and the correlation between PCR status and disease-free survival is now consolidated. Since PCR analysis can rapidly provide indications, about the effectiveness of innovative treatments, the introduction of 'molecular end-points' in clinical studies should be strongly encouraged in order to warrant a rapid evaluation of novel therapeutic strategies. In addition, it is now clear that molecular remission represents a prognostic factor because it is a sort of measurement of the reduction of tumor burden. A similar consideration can be done for the evaluation of in vitro purging procedure: molecular analysis must be included in any protocol of in vitro manipulation of stem cells. Another potentially important application of molecular analysis is the early treatment of patients who show persistence (or increase, if quantitative approaches are used) of molecularly detectable disease, and thus are at high-risk of relapse. Several treatments including adoptive immunotherapy, vaccination strategies and modulation of graft-versus-host disease will probably show greater effectiveness if used to treat small residual tumor burdens instead of overt relapses. This approach is already under evaluation in several hematological tumors including chronic myelogenous leukemia and acute promyelocytic leukemia. 51, 52 A potential problem associated with a more widespread use of PCR-based techniques is the lack of international standardization. Since small differences in assay sensitivity/specificity can easily introduce significant biases in the interpretation of results, great caution should be used in comparing data obtained from different institutions. Centralization of MRD analysis should also be considered mandatory in multicentric studies, in order to obtain fully evaluable results. In future years, efforts should be undertaken to assure greater methodological homogeneity among different centers involved in molecular studies. In this view, a 'consensus conference' to define common guidelines for PCR assays could represent a major progress in the field.
The impact of PCR analysis in the management of indolent lymphomas has been strong and therapeutic evolution in this field has been greatly supported by data obtained from molecular studies. However, it should be stressed that the value of PCR negativity will change after the introduction of anti-CD20 monoclonal antibody. The absence of circulating PCR detectable cells may have a different clinical relevance when obtained after months of high-dose chemotherapy or after a single infusion of anti-CD20. New studies are awaited to validate the prognostic value of PCR analysis in these novel therapeutic settings. It cannot be excluded that PCR analysis will need to be partially readapted in order to address these future issues.
